U.S. Market Community

In a nut shell, I saw Butterfly Network as a medical break through and bought a few hundred shares at a $1.55/shr. and the following news confirmed my reasoning of buying; On November 17, 2025, Butterfly Network’s subsidiary signed a five-year co-development and licensing agreement with Midjourney for exclusive access to its semiconductor-based ultrasound technology, securing a US$15 million upfront payment, US$10 million annual license fees, and further milestone and revenue-sharing potential.Read more

Revenue Growth : GE Vernova is expected to grow its revenue by 13% , contributing to a total revenue of US$77 billion. Earnings Forecast : Estimated earnings for 2030 are US$4.2 billion , translating into a market capitalization of US$270.06 billion , based on a 64.68x price-to-earnings ratio.Read more

I like the prospects of all the optical build out in AI data centers. The only supplier of glass for apple iPhone.Read more

Over the last year, the share price of Procter & Gamble (PG:NYSE) has fallen from around $175 to roughly $140, with most of the decline occurring since March. This weakness may partly reflect layoffs announced earlier in the year amid tariff-related uncertainty, and the stock may now be drifting into oversold territory.Read more

Using the Buffett Value Calculation with P/E = $46.02, Growth Rate = 39.18%, and EPS ttm = $0.55 (source: FinViz, 12/8/25) - the Estimated Share Price is $79.54 with a Buy Price set at $39.77 or less.Read more

The "Molecular Pencil": Why Beam's Technology is Built to Win The investment thesis in Beam Therapeutics is a long-term, high-conviction bet on a fundamental technological shift in genetic medicine. While first-generation gene editors like CRISPR-Cas9 function as "molecular scissors," they are an inherently disruptive tool.Read more

PRME Medicine has just announced the publication of an important article in The New England Journal of Medicine. The article announces success in developing a new treatment using gene editing and stem cell therapy in clinical trials.Read more

I became attracted to this ETF because of it's high percentage of dividends that qualify as long-term, qualified dividends. I don't recall the exact percentage, but it's something in the neighborhood of 62% of dividends being qualified.Read more

The world has been captivated by the artificial intelligence boom, and no company has ridden the wave of investor enthusiasm quite like Microsoft. Buoyed by its strategic partnership with OpenAI and the integration of AI across its product ecosystem, the company's valuation has soared to unprecedented heights.Read more